Press Release
CDEX Inc and GRIFOLS International SA Announce Business Partnership Relationship
CDEX Inc and Grifols International SA to enter into distribution agreement for the ValiMed™ Medication Validation System in Southern Europe.
Tucson, Arizona and Barcelona, Spain – April 9, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding international expansion by announcing today a business partnership agreement with GRIFOLS International SA to distribute ValiMed™ in Spain, Portugal and Italy. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.
“At Grifols we strive to provide hospitals with innovative products and services that improve the quality, efficiency and effectiveness of patient care”, said Xavier Guix, Marketing Director at Grifols International SA. “ValiMed integrates well with that vision by bringing new and unique standards to enhance patient medication safety. We are very excited about this new relationship with CDEX.”
“We are very honored that a Company like Grifols, driven by high quality and ethical standards is taking our products on board and we look forward to developing a strong and long lasting relationship that will directly benefit our customers in Southern Europe” said Malcolm Philips, CDEX President and CEO. “Patient Medication Safety is a global concern and a top priority in all hospitals. This announcement marks another concrete step in our goal of making ValiMed a safety standard worldwide.”
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Pascal Pouligny (ppoulignyt@cdex-inc.com) at 520.745.5172 X 210.
About GRIFOLS International SA.
Grifols is a holding company specialized in the pharmaceutical hospital sector and present in more than 90 countries. Grifols has been present in healthcare since 1940, creating innovative products and services based on the values of ethics and responsibility. Grifols' activities focus on fulfilling the needs of healthcare professionals working in therapeutics, pharmacy, diagnostics and blood banking. For more than 60 years, Grifols has developed, manufactured and marketed products designed to improve human health. The company manufactures products of proven efficacy, quality and safety. More information about Grifols can be found at grifols.com. Since 2006 the company is present on the stock exchange as GRF.MC and was included on the prestigious IBEx-35 group of companies in Spain starting on January 2008..
Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements. |
